Candida is the most implicated fungal pathogen in the clinical setting. Virulence factors, such as biofilms play important roles in its pathogenesis. Hence, this study aimed to investigate role of staphylococcal bacteriocin in inhibit biofilm and viability of Candida spp. Seventy-two isolates were collected from abscess, wounds and burns . All isolates were reidentified using different examinations. In addition, eight species of previously isolated clinical Candida species, from oral and vaginal cavities of patients with candidiasis, including C. albicans, C. glabrata, C. parasilosis, C. krusei, C. lusitaniae, C. kefyr, C. tropicalis and C. ciferrii, were utilized to check the antimicrobial activity of S. aureus on Candida spp. Agar well diffusion method were used to detect bacteriocin production by S. aureus, whereas only 5 isolates were selected. The antibacterial effect of selected S. aureus isolates were tested against indicators (Pseudomonas aeruginosa, Escherichia coli and Candida albicans). Isolate of S. aureus no.2 was showed the best bacteriocin production. Bacteriocin was purified using ammonium sulfate and dialysis. Different concentrations was utilized to determine sub-minimal inhibitory concentration (sub-MIC) of bacteriocin. Sub-MIC of bacteriocin was utilized to estimate its inhibitory effect on viability of Candida spp. Bacteriocin showed the maximal inhibition percentage against C. parapsilosis CV26 with 85.42%, followed by C. tropicalis CO49 with 80.49%. The viability of C. kefyr CO45, C. krusei CO41, C. glabrata CO38, C. albicans CV5 and C. lusitaniae was inhibited by 77.78, 75.41, 74.67, 71.43 and 70.18%, respectively. In addition, 69.84 and 64.62% of C. albicans CV1 and C. ciferrii. Using microtiter plate, sub-MIC of bacteriocin showed maximal inhibitory effect against C. ciferrii with 82.26%, followed by C. lusitaniae with 80.4%, the biofilm formation of C. parapsilosis CV26 and C. tropicalis CO49 was inhibited by 80.49% and 79.82%, respectively.